Latest papers

Prognostic markers in gliomas.

5-Aza-2′-deoxycytidine treatment induces skeletal myogenic differentiation of mouse dental pulp stem cells

Primary CNS lymphoma in the elderly: temozolomide therapy and MGMT status.

Aberrant gene methylation in the lymph nodes provides a possible marker for diagnosing micrometastasis in gastric cancer.

Porcupine expression is associated with the expression of S100P and other cancer-related molecules in non-small cell lung carcinoma.

[No correlation between the sensitivity to 5-aza-dC and the global DNA methylation level in hepatocellular carcinoma cells].

Chemotherapy resistance abrogation in metastatic melanoma.

Emodin, aloe-emodin and rhein induced DNA damage and inhibited DNA repair gene expression in SCC-4 human tongue cancer cells.

Long-term survival of a patient with glioblastoma.

Gene silencing of DNA methyltransferases by RNA interference in bovine fibroblast cells.

O-methylguanine-DNA methyltransferase immunoexpression in a double pituitary adenoma: case report.

Resistance to 5-aza-2'-deoxycytidine in genic regions compared to non-genic repetitive sequences.

The characterization of restriction endonucleases: the work of Hamilton Smith.

MicroRNA-181 family predicts response to concomitant chemoradiotherapy with temozolomide in glioblastoma patients.

Decitabine.

Current therapeutic paradigms in glioblastoma.

Promoter histone H3 lysine 9 di-methylation is associated with DNA methylation and aberrant expression of p16 in gastric cancer cells.

Association between MGMT promoter hypermethylation and p53 mutation in glioblastoma.

Utility of gene promoter methylation in prediction of response to platinum-based chemotherapy in epithelial ovarian cancer (EOC).